Search CLNN
Clene Inc.
Nasdaq · CIK 1822791
Last close4.08
Daily change+0.06 (1.49%)
10 Years gain-97.91%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CLNN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
47.0Momentum
0.0Acceleration
0.0Confidence
78.0Annual Revenue6
Quarterly Revenue21
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality18.7 / 25
Capital Efficiency16.2 / 20
Balance Sheet9.7 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 2.803 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 4282.1941 percentage points.
Key Metrics
Revenue Growth TTM-55.72%OK
Revenue CAGR 3Y-24.94%OK
Gross Margin75.51%OK
Operating Margin-12,870.75%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $200,000.00 | $157,000.00 | -$23.08M | -$18.55M | -$18.59M | 78.5% | -11,541.5% | -9,292.5% | n/a | n/a |
| 2025 FY Dec 31, 2024 | $342,000.00 | $272,000.00 | -$33.09M | -$21.33M | -$21.34M | 79.53% | -9,676.32% | -6,240.06% | n/a | n/a |
| 2024 FY Dec 31, 2023 | $654,000.00 | $533,000.00 | -$40.54M | -$30.17M | -$30.50M | 81.5% | -6,198.78% | -4,663.76% | n/a | n/a |
| 2023 FY Dec 31, 2022 | $473,000.00 | $447,000.00 | -$48.41M | -$39.01M | -$44.19M | 94.5% | -10,234.46% | -9,342.49% | n/a | n/a |
| 2022 FY Dec 31, 2021 | $723,000.00 | $434,000.00 | -$49.98M | -$34.62M | -$35.96M | 60.03% | -6,912.59% | -4,973.17% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $147,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-027828, 0001437749-25-034613 |
| Revenue Growth TTM | -55.72% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-027828, 0001437749-25-034613 |
| Revenue CAGR 3Y | -24.94% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-008502 |
| Revenue CAGR 5Y | -0.59% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-008502 |
| Gross Profit CAGR 3Y | -29.44% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-008502 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027828, 0001437749-25-034613 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 75.51% | Gross Profit / Revenue | OK | 0001437749-26-027828, 0001437749-25-034613 |
| Operating Margin | -12,870.75% | Operating Income / Revenue | OK | 0001437749-26-027828, 0001437749-25-034613 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-027828 |
| Current Ratio | 3.07x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.55x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-26-027828 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001437749-26-008502 |